Merck Sharp & Dohme LLC, 2024-09: FDA-approved label for Stromectol giving human pharmacokinetics: a single 12 mg oral dose produces mean peak plasma concentrations of about 31-47 ng/mL (roughly 0.035-0.053 micromolar) at about 4 hours, with a plasma half-life of about 18 hours.
In two studies, after single 12 mg doses of STROMECTOL in fasting healthy volunteers (representing a mean dose of 165 mcg/kg), the mean peak plasma concentrations of the major component (H2B1a) were 46.6 (±21.9) (range: 16.4-101.1) and 30.6 (±15.6) (range: 13.9-68.4) ng/mL, respectively, at approximately 4 hours after dosing.
Clinical Pharmacology, Pharmacokinetics (label section)
Merck Sharp & Dohme LLC, 2024-09: FDA-approved label for Stromectol giving human pharmacokinetics: a single 12 mg oral dose produces mean peak plasma concentrations of about 31-47 ng/mL (roughly 0.035-0.053 micromolar) at about 4 hours, with a plasma half-life of about 18 hours. Study type: regulatory label (record field, not prose argument). N: two PK studies in fasting healthy volunteers. Country: USA (label) with international trial sites. Dose: 12 mg single oral dose (about 165 mcg/kg), and multiple-dose 30-120 mg in a further study. Funder/maker: Merck Sharp & Dohme LLC. Comparator: n/a. This is the reference human exposure figure against which in vitro anticancer concentrations of 2-20 micromolar are compared; at 875 g/mol, 46.6 ng/mL is approximately 0.053 micromolar. No direct PDF link is given because accessdata.fda.gov refused automated access (abuse-detection block) on 2026-11-20; the DailyMed page was opened and the excerpt copied from it. Archive URL intentionally blank. Also filed as IVA-42, IVA-23, IVF-01, IVE-01 (claims C1, C10, C6, C9). Study type: regulatory record.
